Literature DB >> 21353794

A prospective randomized trial for postoperative vs. preoperative adjuvant radiotherapy for muscle-invasive bladder cancer.

Hassan Abd El-Monim1, Manal M El-Baradie, Alaa Younis, Yaser Ragab, Ashraf Labib, Inas El-Attar.   

Abstract

PURPOSE: Although radical cystectomy is considered to be the primary treatment for muscle-invasive bladder cancer, it is associated with unfavorable outcome. Local recurrence is still a major problem. Survival rates as well as quality of live are far from being satisfactory. Postoperative radiotherapy is considered the standard adjuvant treatment in the NCI-Egypt. This is a prospective randomized study conducted to compare preoperative with postoperative radiotherapy as regard the survival and complication rates. PATIENTS AND METHODS: In the period from May, 2004 to June 2007, 100 eligible patients were included into the study, 50 patients in each treatment arm. Pelvic irradiation was identical in both groups aiming at 50 Gy/25 Fs/5 wk. Radical cystectomy was the standard surgery. Locoregional control, survival rates, and complications rates were compared in both arms.
RESULTS: Patients had a median follow-up period of 32 months (range 0-69 months). Patients had an average age of 54.8 ± 9.5 years with a male/female ratio 3:1. In the present study, transitional cell carcinoma constitutes (51%), while squamous cell carcinoma was reported in 46% of cases. Grades II and III pathology were 81% and 17%, respectively. Pathological stage P2b was encountered in 39.5% of the patients followed by P3b (33.3%) and P3a (14.6%). For the preoperative group, the 3-year overall survival, disease-free survival, locoregional control, and metastases-free survival rates were 53.4%, 47.4%, 89.3%, and 61.5%, respectively. The corresponding figures for the postoperative group were 51.8%, 34.1%, 80.6%, and 55.7% for the postoperative group. None of the patients had serious radiation reactions.
CONCLUSION: In our study, preoperative radiotherapy was almost equivalent to postoperative radiation therapy as regard OS, DFS, as well as complication rates. Given the recent physical developments in radiation therapy techniques and the biological rationale for treating the pelvis after cystectomy, adjuvant radiotherapy should be re-evaluated world wide. Preoperative radiotherapy may re-emerge as a useful tool for adjuvant treatment.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21353794     DOI: 10.1016/j.urolonc.2011.01.008

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  10 in total

1.  Immunologic Consequences of Sequencing Cancer Radiotherapy and Surgery.

Authors:  Juan Carlos López Alfonso; Jan Poleszczuk; Rachel Walker; Sungjune Kim; Shari Pilon-Thomas; Jose J Conejo-Garcia; Hatem Soliman; Brian Czerniecki; Louis B Harrison; Heiko Enderling
Journal:  JCO Clin Cancer Inform       Date:  2019-04

Review 2.  Radiotherapy with radical cystectomy for bladder cancer: A systematic review and meta-analysis.

Authors:  Kristen Mcalpine; Dean A Fergusson; Rodney H Breau; Luke F Reynolds; Risa Shorr; Scott C Morgan; Libni Eapen; Ilias Cagiannos; Chris Morash; Luke T Lavallée
Journal:  Can Urol Assoc J       Date:  2018-05-28       Impact factor: 1.862

Review 3.  Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider?

Authors:  Paul Sargos; Brian C Baumann; Libni J Eapen; Amit Bahl; Vedang Murthy; Guilhem Roubaud; Mathieu Orré; Jason A Efstathiou; Shahrokh Shariat; Stephane Larré; Pierre Richaud; John P Christodouleas
Journal:  Transl Androl Urol       Date:  2016-10

Review 4.  The Rationale for Post-Operative Radiation in Localized Bladder Cancer.

Authors:  Brian C Baumann; Paul Sargos; Libni J Eapen; Jason A Efstathiou; Ananya Choudhury; Amit Bahl; Vedang Murthy; Leslie K Ballas; Valérie Fonteyne; Pierre M Richaud; Mohamed S Zaghloul; John P Christodouleas
Journal:  Bladder Cancer       Date:  2017-01-27

5.  Adjuvant treatment following radical cystectomy for muscle-invasive urothelial carcinoma and variant histologies: Is there a role for radiotherapy?

Authors:  Kevin Lm Chua; Grace Kusumawidjaja; Jure Murgic; Melvin Lk Chua
Journal:  ESMO Open       Date:  2017-03-07

6.  Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer: A retrospective multicenter study.

Authors:  Mathieu Orré; Igor Latorzeff; Aude Fléchon; Guilhem Roubaud; Véronique Brouste; Richard Gaston; Thierry Piéchaud; Pierre Richaud; Olivier Chapet; Paul Sargos
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

7.  High Apelin Level Indicates a Poor Prognostic Factor in Muscle-Invasive Bladder Cancer.

Authors:  Long Yang; Yan-Lei Li; Xiao-Qing Li; Zheng Zhang
Journal:  Dis Markers       Date:  2019-03-07       Impact factor: 3.434

8.  Bone Marrow Suppression during Postoperative Radiation for Bladder Cancer and Comparative Benefit of Proton Therapy-Phase 2 Trial Secondary Analysis.

Authors:  Robert H Press; Joseph W Shelton; Chao Zhang; Quang Dang; Sibo Tian; Timothy Shu; Crystal S Seldon; Shaakir Hasan; Ashesh B Jani; Jun Zhou; Mark W McDonald
Journal:  Int J Part Ther       Date:  2021-07-06

Review 9.  Oncologic Impact and Safety of Pre-Operative Radiotherapy in Localized Prostate and Bladder Cancer: A Comprehensive Review from the Cancerology Committee of the Association Française d'Urologie.

Authors:  Paul Sargos; Stéphane Supiot; Gilles Créhange; Gaëlle Fromont-Hankard; Eric Barret; Jean-Baptiste Beauval; Laurent Brureau; Charles Dariane; Gaëlle Fiard; Mathieu Gauthé; Romain Mathieu; Guilhem Roubaud; Alain Ruffion; Raphaële Renard-Penna; Yann Neuzillet; Morgan Rouprêt; Guillaume Ploussard
Journal:  Cancers (Basel)       Date:  2021-12-02       Impact factor: 6.639

Review 10.  Squamous cell carcinoma of the urinary bladder: Systematic review of clinical characteristics and therapeutic approaches.

Authors:  Jeremy W Martin; Estrella M Carballido; Ahmed Ahmed; Bilal Farhan; Rahul Dutta; Cody Smith; Ramy F Youssef
Journal:  Arab J Urol       Date:  2016-08-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.